Publication Date
2-1-2023
Journal
Current Protocols
DOI
10.1002/cpz1.652
PMID
36757287
PMCID
PMC9923875
PubMedCentral® Posted Date
2-1-2024
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Animals, Animals, Genetically Modified, Drosophila melanogaster, Proteomics, Workflow, DNA, Drosophila, Selection, Counterselection, Multiplexed, Transgenesis, Genetics, Genetic manipulation, Drosophila melanogaster
Abstract
We recently described a set of four selectable and two counterselectable markers that provide resistance and sensitivity, respectively, against their corresponding drugs using the model organism Drosophila melanogaster. The four selectable markers provide animal resistance against G418 sulfate, Puromycin HCl, Blasticidin S, or Hygromycin B, while the two counterselection markers make animals sensitive to Ganciclovir/Acyclovir, or 5-Fluorocytosine. Unlike classical phenotypic markers, visual or fluorescent, which require extensive screening progeny of a genetic cross for desired genotypes, resistance and sensitivity markers eliminate this laborious procedure by directly selecting for, or counterselecting against, the desired genotypes. We demonstrated the usefulness of these markers with three applications: 1) generating dual transgenic animals for binary overexpression (e.g., GAL4/UAS) analysis in a single step through the process of co-injection, followed by co-selection resulting in co-transgenesis; 2) obtaining balancer chromosomes that are both selectable and counterselectable to manipulate crossing schemes for, or against, the presence of the modified balancer chromosome; and, 3) making both selectable and fluorescently tagged P[acman] BAC transgenic animals for gene expression and proteomic analysis. Here we describe detailed procedures on how to use these drug-based selection and counterselection markers in the fruit fly Drosophila melanogaster in making dual transgenic animals for binary overexpression as an example. Dual transgenesis integrates site-specifically into two sites in the genome in a single step, both components of the binary GAL4/UAS overexpression system, a G418 sulfate-selectable GAL4 transactivator plasmid and a Blasticidin S-selectable UAS responder plasmid. The process involves co-injecting both plasmids, followed by co-selection using G418-sulfate and Blasticidin S, resulting in co-transgenesis of both plasmids in the fly genome. We demonstrate functionality of the procedure by including the expression pattern obtained after dual transgenesis of both plasmids. We provide protocols on how to prepare drugged fly food vials, determine the effective drug concentration for markers used during transgenic selection and counterselection strategies, how to prepare and confirm plasmid DNA for microinjection, followed by the microinjection procedure itself and conclude by setting up cross schemes to isolate desired progeny through selection and/or counterselection. These protocols can be easily adapted to any combination of the six selectable and counterselectable markers we described, or any new marker that is resistant or sensitive to a novel drug. Protocols on how to build plasmids by synthetic assembly DNA cloning or modify plasmids by serial recombineering to perform a plethora of selection, counterselection or any other genetic strategies are presented in two accompanying Current Protocols articles (Current Protocols #2 and Current Protocols #3), respectively.
Basic Protocol 1:
Preparing drugged fly food vials for transgenic selection and counterselection strategies using Drosophila melanogaster.
Basic Protocol 2:
Determination of the effective drug concentration for resistance and sensitivity markers used during transgenic selection and counterselection strategies using Drosophila melanogaster.
Basic Protocol 3:
Preparing and confirming plasmid DNA for microinjection to perform transgenic selection and counterselection strategies using Drosophila melanogaster.
Basic Protocol 4:
Microinjecting plasmid DNA into fly embryos to perform transgenic selection and counterselection strategies using Drosophila melanogaster.
Basic Protocol 5:
Crossing schemes to isolate desired progeny through transgenic selection and counterselection strategies using Drosophila melanogaster.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Genetics and Genomics Commons, Medical Genetics Commons, Medical Molecular Biology Commons, Medical Specialties Commons